TAM
IMNM icon

Titleist Asset Management’s Immunome IMNM Stock Holding History

Titleist Asset Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-44,767
Closed -$654K – 320
2024
Q3 		$654K Sell
44,767
-19,200
-30% -$273K 0.09% 148
2024
Q2 		$774K Buy
+63,967
New +$1M 0.12% 126

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Titleist Asset Management's IMNM Position: Q4 2024 in Review

Titleist Asset Management sold out of Immunome (IMNM) in Q4 2024, closing a stake of 44,767 shares — an estimated $654K sold.

Titleist Asset Management first reported a position in IMNM in Q2 2024 and held it in 2 quarters. The position peaked at $774K in Q2 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

  • Titleist Asset Management reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
  • Titleist Asset Management sold 44,767 Immunome shares in Q4 2024, an estimated $654K.
  • Titleist Asset Management first reported a position in Immunome in Q2 2024 and held it in 2 quarters.
  • Titleist Asset Management's Immunome position peaked at $774K in Q2 2024.
  • 120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on Titleist Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.